Thomas Hübschle
14 Papers
Thomas Hübschle is an academic researcher. The author has contributed to research in topics: Ventricular remodeling & Cathepsin A. The author has an hindex of 8, co-authored 14 publications.
Chat about Author
Papers
Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies
Paulus Wohlfart,Wolfgang Linz,Thomas Hübschle,Dominik Linz,Jochen Huber,Sibylle Hess,Daniel Crowther,Ulrich Werner,Hartmut Ruetten +8 more
TL;DR: Patients with cardiac dysfunction are currently being recruited for a randomized, double-blind, placebo-controlled, multicenter study with lixisenatide, which reduces in an acute setting infarct-size and improved cardiac function when administered long-term after ischemia-reperfusion injury.
Novel β-amino acid derivatives as inhibitors of cathepsin A.
Sven Ruf,Christian Buning,Herman Schreuder,Georg Horstick,Wolfgang Linz,Thomas Olpp,Josef Pernerstorfer,Katrin Hiss,Katja Kroll,Aimo Kannt,Markus Kohlmann,Dominik Linz,Thomas Hübschle,Hartmut Rütten,Klaus Wirth,Thorsten Schmidt,Thorsten Sadowski +16 more
TL;DR: Novel β-amino acid derivatives as inhibitors of CatA showed beneficial ADME and pharmacokinetic profiles, and their binding modes were established by X-ray crystallography, which led to the identification of a hitherto unknown pathophysiological role ofCatA in cardiac hypertrophy.
48
Animal Models of Diabetic Macrovascular Complications: Key Players in the Development of New Therapeutic Approaches
Suvi E. Heinonen,Guillem Genové,Eva Bengtsson,Thomas Hübschle,Lina Åkesson,Katrin Hiss,Agnes Benardeau,Seppo Ylä-Herttuala,Ann-Cathrine Jönsson-Rylander,Maria F. Gomez +9 more
TL;DR: Information is gathered on the available experimental animal models of diabetic macrovascular complications and evaluates their pros and cons for research purposes as well as for drug development.
Cardiac remodeling and myocardial dysfunction in obese spontaneously hypertensive rats.
Dominik Linz,Mathias Hohl,Felix Mahfoud,Jan-Christian Reil,Wolfgang Linz,Thomas Hübschle,Hans-Paul Juretschke,Claudia Neumann-Häflin,Hartmut Rütten,Michael Böhm +9 more
TL;DR: In addition to hypertension alone, metabolic syndrome and obesity adds to the myocardial phenotype by aggravating diastolic dysfunction and a progression towards systolic dysfunction in SHR-ob, a useful model to develop new interventional and pharmacological treatment strategies for hypertensive heart disease and metabolic disorders.
Inhibition of CatA: an emerging strategy for the treatment of heart failure
Sven Ruf,Christian Buning,Herman Schreuder,Wolfgang Linz,Thomas Hübschle,Dominik Linz,Hartmut Ruetten,Klaus Wirth,Thorsten Sadowski +8 more
TL;DR: Pharmacological studies in rodents indicate a remarkable influence of CatA inhibition on cardiovascular disease progression and identify CatA as a promising novel target for the treatment of heart failure.
20